Surveillance Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, Rockville, MD.
Healthcare Delivery Research Program, Division of Cancer Control and Population, Sciences, National Cancer Institute, Rockville, MD.
J Natl Cancer Inst Monogr. 2020 May 1;2020(55):39-45. doi: 10.1093/jncimonographs/lgz034.
Health-care claims are of increasing utility as a rich, real-world data resource for conducting treatment-related cancer research. However, multiple dynamic coding nomenclatures exist, leading to study variability. To promote increased standardization and reproducibility, the National Cancer Institute (NCI) developed the Cancer Medications Enquiry Database (CanMED)-Healthcare Common Procedure Coding System (HCPCS) within the Observational Research in Oncology Toolbox.
The CanMED-HCPCS includes codes for oncology medications that a) have a US Food and Drug Administration-approved indication for cancer treatment or treatment-related symptom management; b) are present in National Comprehensive Cancer Network guidelines; or c) carry an orphan drug designation for treatment or management of cancer. Included medications and their HCPCS codes were primarily identified based on Center for Medicare and Medicaid Services annual HCPCS Indices (2012-2018). To demonstrate the utility of the CanMED-HCPCS, use of systemic treatment for stage II-IV colorectal cancer patients included in the Surveillance, Epidemiology, and End Results-Medicare data (2007-2013) was assessed.
The CanMED-HCPCS (v2018) includes 332 HCPCS codes for cancer-related medications: chemotherapy (156), immunotherapy (74), hormonal therapy (54), and ancillary therapy (48). Observed treatment trends within the NCI Surveillance, Epidemiology, and End Results-Medicare data were as expected; utilization of each treatment type increased with stage, and immunotherapy was largely confined to use among stage IV patients.
The CanMED-HCPCS provides a comprehensive resource that can be used by the research community to facilitate systematic identification of medications within claims or electronic health data using the HCPCS nomenclature and greater reproducibility of cancer surveillance and health services research.
随着医疗保健索赔作为进行与治疗相关的癌症研究的丰富、真实世界数据资源的用途不断增加,其重要性日益凸显。然而,由于存在多种动态编码命名法,导致研究结果存在差异。为了提高标准化和可重复性,美国国家癌症研究所(NCI)在观察性肿瘤学工具包内开发了癌症药物查询数据库(CanMED)-医疗保健通用程序编码系统(HCPCS)。
CanMED-HCPCS 包含用于癌症治疗或与治疗相关的症状管理的美国食品和药物管理局(FDA)批准的癌症治疗适应证的药物、国家综合癌症网络指南中存在的药物或用于治疗或管理癌症的孤儿药物指定的药物的代码。纳入的药物及其 HCPCS 代码主要根据医疗保险和医疗补助服务中心年度 HCPCS 索引(2012-2018 年)确定。为了展示 CanMED-HCPCS 的实用性,评估了监测、流行病学和最终结果-医疗保险数据(2007-2013 年)中纳入的 II-IV 期结直肠癌患者使用全身治疗的情况。
CanMED-HCPCS(v2018)包含 332 个与癌症相关的药物 HCPCS 代码:化疗(156)、免疫疗法(74)、激素疗法(54)和辅助疗法(48)。在 NCI 监测、流行病学和最终结果-医疗保险数据中观察到的治疗趋势与预期相符;每种治疗类型的使用率随着分期的增加而增加,免疫疗法主要局限于 IV 期患者使用。
CanMED-HCPCS 提供了一个全面的资源,研究界可以使用该资源通过 HCPCS 命名法在索赔或电子健康数据中系统地识别药物,并提高癌症监测和卫生服务研究的可重复性。